Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Respiratory Syncytial Virus Market to Reach USD 4.54 Billion by 2033 as Global Uptake of Next-Generation Vaccines & Monoclonal Antibodies Accelerates

prnewswire.com
PFE Pfizer's Abrysvo vaccine for adults and pregnant women is a key driver in the rapidly expanding RSV market, contributing to a multi-billion dollar opportunity in immunization. GSK GSK's Arexvy vaccine for adults is a significant contributor to the growth of the RSV market, creating a substantial revenue stream from elder immunization. AZN AstraZeneca, in partnership with Sanofi, is disrupting infant protection with Nirsevimab, a monoclonal antibody that significantly expands coverage and market share in the RSV prophylaxis sector. SNY Sanofi, in partnership with AstraZeneca, is a key player in the RSV market with Nirsevimab, a highly effective monoclonal antibody for infant protection, driving significant market expansion. MRK Merck & Co. is mentioned in the competitive landscape of the RSV market, but the article does not provide specific details on their current or future contributions to this market. MRNA Moderna is listed as a competitor in the RSV market, but the article does not detail their specific products or market impact within this sector.

AUSTIN, Texas and TOKYO, Dec. 1, 2025 /PRNewswire/ -- According to DataM Intelligence, the Respiratory Syncytial Virus (RSV) Market Size reached USD 1.95 billion in 2024 and is projected to advance to USD 4.54 billion by 2033, expanding at a strong CAGR of 9.9% during 2025–2033.

This surge is driven by unprecedented clinical momentum in RSV prevention-including the world's first adult RSV vaccines, dramatic expansion of monoclonal antibody prophylaxis in infants, and global recognition of RSV as a major public health priority. With RSV responsible for more than 33 million lower respiratory infections and 118,000 infant deaths annually, the market is transitioning from a long-standing therapeutics gap to a rapidly evolving vaccine-led era.

Download PDF Brochure: https://www.datamintelligence.com/download-sample/respiratory-syncytial-virus-market

Browse in-depth TOC on "Respiratory Syncytial Virus (RSV) Market"

62 – Tables

57 – Figures

159 – Pages

A New Vaccination Era: Why the RSV Market Is Scaling Faster Than Ever Before

In the past two years, RSV has shifted from being an overlooked seasonal virus to one of the most aggressively targeted infectious diseases in the pharmaceutical pipeline. Major drivers shaping the market include:

1. First-Ever Adult RSV Vaccines Transform the Market

GSK's Arexvy and Pfizer's Abrysvo-approved for adults ≥60 and pregnant women-have created a multi-billion-dollar opportunity in elder immunization and maternal immunization.

2. Breakthrough Monoclonal Antibody Prophylaxis for Infants

Nirsevimab (Sanofi/AstraZeneca) is disrupting infant protection with only one dose per RSV season, expanding coverage by 5x compared with earlier products like palivizumab.

3. Escalating RSV Hospitalizations Across Age Groups

An aging demographic, rising comorbidities, and viral seasonality shifts have increased hospital RSV admissions by 22% YoY in the U.S. and several Asian nations.

4. Pipeline Acceleration in Antivirals

Multiple oral and inhaled antiviral candidates from global pharma companies aim to reduce severe RSV outcomes across all age groups.

Combined, these factors position RSV as the fastest-growing respiratory infection market globally-second only to influenza.

Market Segmentation

By Drug Class (Vaccines, Monoclonal Antibodies, Antivirals)

Vaccines

Vaccines represented the largest segment in 2024, contributing 56% (USD 1.09 billion) of global revenue. Adult RSV vaccination and maternal immunization programs are expanding rapidly across the U.S., Japan, Europe, and select Asia-Pacific markets.

Monoclonal Antibodies

Monoclonal antibodies accounted for 33% (USD 644 million) of the market. Nirsevimab's high-efficacy, single-dose seasonal protection has dramatically expanded infant immunization eligibility and uptake.

Antivirals

Antivirals held 11% (USD 214 million). Oral and inhaled antivirals remain essential for high-risk adults and immunocompromised patients, with strong pipeline potential expected to increase segment share by 2030.

By Age Group (Infants & Children, Adults, Geriatric)

Infants & Children

This segment accounted for 48% (USD 936 million) of 2024 global revenue.

Pediatric RSV remains the primary disease burden, with infants <6 months making up the majority of hospital admissions and ICU stays.

Adults

Adults represented 29% (USD 566 million), driven by new RSV vaccine approvals for older adults and immunocompromised populations.

Geriatric

The geriatric segment (aged ≥65) accounted for 23% (USD 448 million), reflecting high susceptibility to lower respiratory illnesses, severe complications, and hospitalization.

By Distribution Channel (Hospital Pharmacies, Retail Pharmacies)

Hospital Pharmacies

Hospital pharmacies captured 62% (USD 1.21 billion) of revenue as severe RSV cases-including infants and the elderly-are managed through hospital-based vaccination, monoclonal antibody programs, and inpatient antiviral administration.

Retail Pharmacies

Retail pharmacies represented 38% (USD 741 million), largely driven by adult RSV vaccinations delivered through community pharmacies, primary care clinics, and maternal immunization providers.

Buy This Report with Year-End Offer (Buy 1 report: Get 30% OFF | Buy 2 Reports: Get 50% OFF each! Limited time offer): https://www.datamintelligence.com/buy-now-page?report=respiratory-syncytial-virus-market

Regional Analysis

United States: The World's Largest RSV Market

The U.S. accounted for 44% (USD 858 million) of global RSV revenues in 2024.

Key U.S. Market Indicators

The U.S. market is projected to exceed USD 2.0 billion by 2033, driven by nationwide infant immunization programs and rapid pharmacy-based vaccination expansion.

Japan: Rising Adoption of Adult Vaccines & Infant Antibodies

Japan accounted for 7% (USD 136 million) of global revenues in 2024.

Japan Market Highlights

Japan is projected to reach USD 360+ million by 2033 as adult vaccine coverage accelerates.

Buy This Report with Year-End Offer (Buy 1 report: Get 30% OFF | Buy 2 reports: Get 50% OFF each! Limited time offer): https://www.datamintelligence.com/buy-now-page?report=respiratory-syncytial-virus-market

Competitive Landscape

Pfizer Inc.

GSK plc

Moderna, Inc.

AstraZeneca plc

Sanofi S.A.

Merck & Co., Inc.

The Future of RSV Therapeutics: What will Reshape the Market Through 2033

The RSV therapeutics landscape is evolving faster than any other respiratory market. Key developments expected by 2033 include:

Related Report:

About DataM Intelligence

DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.

To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn, and Facebook.

Contact:

Sai Kiran

DataM Intelligence 4market Research LLP

Ground floor, DSL Abacus IT Park, Industrial Development Area

Uppal, Hyderabad, Telangana 500039

USA: +1 877-441-4866

Email: [email protected]

Logo: https://mma.prnewswire.com/media/1858619/3573087/DataM_Intelligence_Logo.jpg

SOURCE DataM Intelligence 4 Market Research LLP